JP2019511214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511214A5 JP2019511214A5 JP2018545335A JP2018545335A JP2019511214A5 JP 2019511214 A5 JP2019511214 A5 JP 2019511214A5 JP 2018545335 A JP2018545335 A JP 2018545335A JP 2018545335 A JP2018545335 A JP 2018545335A JP 2019511214 A5 JP2019511214 A5 JP 2019511214A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- variant
- fragment
- cancer
- cell receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023053020A JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305222P | 2016-03-08 | 2016-03-08 | |
| US62/305,222 | 2016-03-08 | ||
| GB1603987.7 | 2016-03-08 | ||
| GBGB1603987.7A GB201603987D0 (en) | 2016-03-08 | 2016-03-08 | Uterine cancer treatments |
| PCT/EP2017/054908 WO2017153247A1 (en) | 2016-03-08 | 2017-03-02 | Uterine cancer treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023053020A Division JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019511214A JP2019511214A (ja) | 2019-04-25 |
| JP2019511214A5 true JP2019511214A5 (enExample) | 2020-04-16 |
Family
ID=55859178
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545335A Pending JP2019511214A (ja) | 2016-03-08 | 2017-03-02 | 子宮がん治療法 |
| JP2023053020A Pending JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023053020A Pending JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US10138287B2 (enExample) |
| EP (2) | EP4491191A3 (enExample) |
| JP (2) | JP2019511214A (enExample) |
| KR (2) | KR20230019501A (enExample) |
| CN (2) | CN109475596B (enExample) |
| AR (1) | AR108035A1 (enExample) |
| AU (2) | AU2017229149B2 (enExample) |
| BR (1) | BR112018015545A2 (enExample) |
| CA (1) | CA3015932A1 (enExample) |
| CL (3) | CL2018002508A1 (enExample) |
| CO (1) | CO2018010284A2 (enExample) |
| CR (3) | CR20210038A (enExample) |
| EA (1) | EA201891994A1 (enExample) |
| ES (1) | ES3005964T3 (enExample) |
| GB (1) | GB201603987D0 (enExample) |
| IL (1) | IL261468A (enExample) |
| MA (2) | MA49295A (enExample) |
| MX (2) | MX2018010779A (enExample) |
| MY (1) | MY189796A (enExample) |
| PE (1) | PE20181490A1 (enExample) |
| PH (2) | PH12022551120A1 (enExample) |
| SG (2) | SG11201807300PA (enExample) |
| TW (2) | TWI771694B (enExample) |
| WO (1) | WO2017153247A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| KR20200119840A (ko) | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CR20230295A (es) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| CN114908167A (zh) * | 2022-05-04 | 2022-08-16 | 重庆大学附属肿瘤医院 | Svil表达水平检测试剂在制备卵巢癌干性诊断试剂中的应用 |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN116024341B (zh) * | 2022-11-25 | 2024-08-30 | 重庆医科大学 | 乳腺癌标志物及其应用 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US5283190A (en) | 1989-07-31 | 1994-02-01 | Traish Adbulmaged M | Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1294748B1 (en) | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| FR2823221B1 (fr) | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| KR100739118B1 (ko) * | 2005-07-22 | 2007-07-13 | 이제호 | Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자의 신규한 용도 |
| JP4926966B2 (ja) * | 2005-08-18 | 2012-05-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ドーパミン産生ニューロン増殖前駆細胞マーカーＭｓｘ１／２ |
| DE602005020046D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| CN1920036A (zh) * | 2006-03-29 | 2007-02-28 | 山东中医药大学 | 猕猴孕酮受体基因片段及其应用 |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| HUE025636T2 (en) | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| US9439944B2 (en) * | 2008-04-22 | 2016-09-13 | Sungyunkwan University Foundation For Corporate Collaboration | Agent that inhibits angiogenesis and metastasis targeting mTOR signaling pathway |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| TWI404748B (zh) | 2009-11-10 | 2013-08-11 | Enrestec Inc | 連續式裂解系統及其應用 |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| EP2632955A1 (en) | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| SG191154A1 (en) * | 2010-12-14 | 2013-07-31 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2014011465A2 (en) * | 2012-07-13 | 2014-01-16 | Albert Einstein College Of Medicine Of Yeshiva University | Aptamer-targeted antigen delivery |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI714869B (zh) * | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) * | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| CR20230131A (es) | 2015-05-06 | 2023-06-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497) |
| IL292864A (en) | 2015-08-28 | 2022-07-01 | Immatics Biotechnologies Gmbh | New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
-
2016
- 2016-03-08 GB GBGB1603987.7A patent/GB201603987D0/en not_active Ceased
-
2017
- 2017-03-02 CR CR20210038A patent/CR20210038A/es unknown
- 2017-03-02 SG SG11201807300PA patent/SG11201807300PA/en unknown
- 2017-03-02 WO PCT/EP2017/054908 patent/WO2017153247A1/en not_active Ceased
- 2017-03-02 CN CN201780016147.1A patent/CN109475596B/zh not_active Expired - Fee Related
- 2017-03-02 CR CR20180460A patent/CR20180460A/es unknown
- 2017-03-02 EP EP24020331.5A patent/EP4491191A3/en not_active Withdrawn
- 2017-03-02 JP JP2018545335A patent/JP2019511214A/ja active Pending
- 2017-03-02 KR KR1020237002840A patent/KR20230019501A/ko not_active Ceased
- 2017-03-02 MA MA049295A patent/MA49295A/fr unknown
- 2017-03-02 MY MYPI2018703020A patent/MY189796A/en unknown
- 2017-03-02 CN CN202410747770.6A patent/CN118894905A/zh active Pending
- 2017-03-02 PE PE2018001580A patent/PE20181490A1/es unknown
- 2017-03-02 BR BR112018015545-4A patent/BR112018015545A2/pt not_active IP Right Cessation
- 2017-03-02 AU AU2017229149A patent/AU2017229149B2/en not_active Ceased
- 2017-03-02 PH PH1/2022/551120A patent/PH12022551120A1/en unknown
- 2017-03-02 EP EP17709931.4A patent/EP3426281B1/en active Active
- 2017-03-02 KR KR1020187028243A patent/KR102493344B1/ko active Active
- 2017-03-02 SG SG10202008070XA patent/SG10202008070XA/en unknown
- 2017-03-02 ES ES17709931T patent/ES3005964T3/es active Active
- 2017-03-02 EA EA201891994A patent/EA201891994A1/ru unknown
- 2017-03-02 MX MX2018010779A patent/MX2018010779A/es unknown
- 2017-03-02 CR CR20210036A patent/CR20210036A/es unknown
- 2017-03-02 MA MA43466A patent/MA43466A1/fr unknown
- 2017-03-02 CA CA3015932A patent/CA3015932A1/en active Pending
- 2017-03-06 US US15/451,167 patent/US10138287B2/en active Active
- 2017-03-08 TW TW109119177A patent/TWI771694B/zh not_active IP Right Cessation
- 2017-03-08 TW TW106107560A patent/TWI731945B/zh not_active IP Right Cessation
- 2017-03-08 AR ARP170100576A patent/AR108035A1/es not_active Application Discontinuation
-
2018
- 2018-08-28 PH PH12018501828A patent/PH12018501828A1/en unknown
- 2018-08-29 IL IL261468A patent/IL261468A/en unknown
- 2018-09-03 CL CL2018002508A patent/CL2018002508A1/es unknown
- 2018-09-06 MX MX2022003884A patent/MX2022003884A/es unknown
- 2018-09-26 CO CONC2018/0010284A patent/CO2018010284A2/es unknown
- 2018-10-08 US US16/154,457 patent/US10669325B2/en not_active Expired - Fee Related
- 2018-11-02 US US16/178,674 patent/US10266581B2/en active Active
- 2018-11-02 US US16/178,672 patent/US10239932B2/en active Active
-
2019
- 2019-03-11 US US16/298,652 patent/US20190194289A1/en not_active Abandoned
- 2019-11-12 US US16/680,634 patent/US11390660B2/en active Active
-
2020
- 2020-07-20 CL CL2020001897A patent/CL2020001897A1/es unknown
- 2020-07-20 CL CL2020001898A patent/CL2020001898A1/es unknown
-
2021
- 2021-06-04 US US17/339,371 patent/US12221467B2/en active Active
- 2021-06-11 US US17/345,553 patent/US12234276B2/en active Active
- 2021-07-26 AU AU2021207620A patent/AU2021207620A1/en not_active Abandoned
-
2023
- 2023-03-29 JP JP2023053020A patent/JP2023093483A/ja active Pending
-
2025
- 2025-01-07 US US19/012,311 patent/US20250145686A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021168652A5 (enExample) | ||
| JP2019502360A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2021514178A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2018509135A5 (enExample) | ||
| JP2018519243A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2018511321A5 (enExample) | ||
| JP2018518937A5 (enExample) | ||
| JP2021535900A5 (enExample) | ||
| JP2017525336A5 (enExample) | ||
| JP2020530759A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2020191862A5 (enExample) | ||
| JP2020182458A5 (enExample) | ||
| JP2022502015A5 (enExample) | ||
| JP2020198875A5 (enExample) | ||
| JP2019516663A5 (enExample) |